{"description":"(continued) As pre-specified in the SAP, AEs across the full study period (Weeks 0-252) were analyzed according to each participant's randomized treatment assignment at Week 0, with participants censored at the time of any dose change or permanent treatment discontinuation. Gender specific events only occurring in male or female participants have had the number of participants at Risk adjusted accordingly.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":171,"description":"* Week 0 to Week 52: Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind (Period 1).\n* Week 52 to Week 248: Participants continued to receive the same placebo or switched to either 2 mg or 4 mg Baricitinib dose administered orally QD (Period 2).","id":"EG000","otherNumAffected":44,"otherNumAtRisk":171,"seriousNumAffected":3,"seriousNumAtRisk":171,"title":"Placebo"},{"deathsNumAffected":0,"deathsNumAtRisk":173,"description":"* Week 0 to Week 52: Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind (Period 1).\n* Week 52 to Week 248: Participants continued to receive the same 2 mg dose or switched to an uptitrated 4 mg Baricitinib dose administered orally QD (Period 2).","id":"EG001","otherNumAffected":85,"otherNumAtRisk":173,"seriousNumAffected":5,"seriousNumAtRisk":173,"title":"2 mg Baricitinib"},{"deathsNumAffected":0,"deathsNumAtRisk":258,"description":"* Week 0 to Week 52: Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind (Period 1).\n* Week 52 to Week 248: Participants continued to receive the same 4 mg dose or switched to a downtitrated 2 mg Baricitinib dose, or receive placebo tablets matched to Baricitinib administered orally QD (Period 2).","id":"EG002","otherNumAffected":133,"otherNumAtRisk":258,"seriousNumAffected":16,"seriousNumAtRisk":258,"title":"4 mg Baricitinib"},{"deathsNumAffected":0,"deathsNumAtRisk":578,"description":"* The extended safety population (All Baricitinib- Extended) included participants who were continuously treated from baseline with baricitinib 2 mg, baricitinib 4 mg, or placebo and were censored at the time of any dose change or after the permanent study drug discontinuation, whichever occurred earlier.\n* In addition, the population included an \"All Baricitinib\" group, including all participants who received at least one dose of baricitinib (2 mg or 4 mg) at any time during the treatment period.","id":"EG003","otherNumAffected":321,"otherNumAtRisk":578,"seriousNumAffected":34,"seriousNumAtRisk":578,"title":"All Baricitinib- Extended"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":171,"numEvents":1},{"groupId":"EG001","numAffected":18,"numAtRisk":173,"numEvents":20},{"groupId":"EG002","numAffected":45,"numAtRisk":258,"numEvents":52},{"groupId":"EG003","numAffected":148,"numAtRisk":578,"numEvents":178}],"term":"Covid-19"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":171,"numEvents":8},{"groupId":"EG001","numAffected":9,"numAtRisk":173,"numEvents":12},{"groupId":"EG002","numAffected":30,"numAtRisk":258,"numEvents":43},{"groupId":"EG003","numAffected":54,"numAtRisk":578,"numEvents":80}],"term":"Nasopharyngitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":171,"numEvents":16},{"groupId":"EG001","numAffected":24,"numAtRisk":173,"numEvents":29},{"groupId":"EG002","numAffected":31,"numAtRisk":258,"numEvents":45},{"groupId":"EG003","numAffected":77,"numAtRisk":578,"numEvents":107}],"term":"Upper respiratory tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":171,"numEvents":4},{"groupId":"EG001","numAffected":18,"numAtRisk":173,"numEvents":24},{"groupId":"EG002","numAffected":20,"numAtRisk":258,"numEvents":29},{"groupId":"EG003","numAffected":60,"numAtRisk":578,"numEvents":84}],"term":"Urinary tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":171,"numEvents":3},{"groupId":"EG001","numAffected":7,"numAtRisk":173,"numEvents":7},{"groupId":"EG002","numAffected":13,"numAtRisk":258,"numEvents":14},{"groupId":"EG003","numAffected":21,"numAtRisk":578,"numEvents":23}],"term":"Blood cholesterol increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":171,"numEvents":1},{"groupId":"EG001","numAffected":3,"numAtRisk":173,"numEvents":5},{"groupId":"EG002","numAffected":17,"numAtRisk":258,"numEvents":25},{"groupId":"EG003","numAffected":32,"numAtRisk":578,"numEvents":49}],"term":"Blood creatine phosphokinase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":171,"numEvents":1},{"groupId":"EG001","numAffected":9,"numAtRisk":173,"numEvents":9},{"groupId":"EG002","numAffected":3,"numAtRisk":258,"numEvents":5},{"groupId":"EG003","numAffected":19,"numAtRisk":578,"numEvents":21}],"term":"Weight increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":171,"numEvents":2},{"groupId":"EG001","numAffected":8,"numAtRisk":173,"numEvents":10},{"groupId":"EG002","numAffected":10,"numAtRisk":258,"numEvents":12},{"groupId":"EG003","numAffected":31,"numAtRisk":578,"numEvents":40}],"term":"Hypercholesterolaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":171,"numEvents":8},{"groupId":"EG001","numAffected":4,"numAtRisk":173,"numEvents":4},{"groupId":"EG002","numAffected":13,"numAtRisk":258,"numEvents":15},{"groupId":"EG003","numAffected":26,"numAtRisk":578,"numEvents":29}],"term":"Back pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":171,"numEvents":12},{"groupId":"EG001","numAffected":17,"numAtRisk":173,"numEvents":37},{"groupId":"EG002","numAffected":35,"numAtRisk":258,"numEvents":45},{"groupId":"EG003","numAffected":74,"numAtRisk":578,"numEvents":119}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":171,"numEvents":5},{"groupId":"EG001","numAffected":4,"numAtRisk":173,"numEvents":5},{"groupId":"EG002","numAffected":14,"numAtRisk":258,"numEvents":16},{"groupId":"EG003","numAffected":31,"numAtRisk":578,"numEvents":36}],"term":"Cough"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":171,"numEvents":4},{"groupId":"EG001","numAffected":11,"numAtRisk":173,"numEvents":13},{"groupId":"EG002","numAffected":16,"numAtRisk":258,"numEvents":17},{"groupId":"EG003","numAffected":40,"numAtRisk":578,"numEvents":44}],"term":"Acne"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Lymphadenopathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Aortic valve incompetence"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":173,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Cardiac failure congestive"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Glaucoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Keratitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Flatulence"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Inguinal hernia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":171,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":578,"numEvents":0}],"term":"Strangulated umbilical hernia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":171,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":173,"numEvents":1},{"groupId":"EG002","numAffected":2,"numAtRisk":258,"numEvents":2},{"groupId":"EG003","numAffected":3,"numAtRisk":578,"numEvents":3}],"term":"Cholecystitis acute"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":2,"numAtRisk":578,"numEvents":2}],"term":"Appendicitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Appendicitis perforated"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Covid-19"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":173,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":3,"numAtRisk":578,"numEvents":3}],"term":"Covid-19 pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Herpes zoster"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":173,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":2,"numAtRisk":578,"numEvents":2}],"term":"Pyelonephritis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Viral infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":173,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":2,"numAtRisk":578,"numEvents":2}],"term":"Ankle fracture"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Hand fracture"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Lumbar vertebral fracture"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Intraocular pressure increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"B-cell lymphoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Benign breast neoplasm"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":110,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":161,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Endometrial cancer stage i"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":64,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":63,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":97,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":215,"numEvents":0}],"term":"Prostate cancer"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":110,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":161,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Uterine leiomyoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Sciatica"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":110,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":161,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Abortion spontaneous"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Product Issues","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Device dislocation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":258,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":2}],"term":"Ureterolithiasis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":110,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":161,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Adenomyosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":64,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":63,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":97,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":215,"numEvents":1}],"term":"Benign prostatic hyperplasia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":110,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":161,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Endometrial hyperplasia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":107,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":110,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":161,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":363,"numEvents":1}],"term":"Heavy menstrual bleeding"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":64,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":63,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":97,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":215,"numEvents":1}],"term":"Varicocele"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":171,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":173,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":258,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":578,"numEvents":1}],"term":"Hypertension"}],"timeFrame":"Baseline up to end of follow up (up to 252 weeks). (AE Description: As pre-specified in the SAP, AE were assessed using the \"safety population\". Given the sequential dose change within Period 2 (Week 52 to Week 248) it was not appropriate to attribute AEs to a single fixed dose, and therefore AEs were not collected separately)."}